Glucagon-like peptides 1 and 2 in health and disease: A review

Abbott, 2005, The inhibitory effects of peripheral administration of peptide YY(3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway, Brain Res, 1044, 127, 10.1016/j.brainres.2005.03.011 Ahren, 2011, The future of incretin-based therapy: novel avenues – novel targets, Diabetes Obes Metab, 13, 158, 10.1111/j.1463-1326.2011.01457.x Astrup, 2009, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study, Lancet, 374, 1606, 10.1016/S0140-6736(09)61375-1 Bagger, 2011, Impaired regulation of the incretin effect in patients with type 2 diabetes, J Clin Endocrinol Metab, 96, 737, 10.1210/jc.2010-2435 Baggio, 2007, Biology of incretins: GLP-1 and GIP, Gastroenterology, 132, 2131, 10.1053/j.gastro.2007.03.054 Baldassano, 2012, Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2, J Endocrinol, 213, 277, 10.1530/JOE-12-0092 Bayliss, 1902, The mechanism of pancreatic secretion, J Physiol, 28, 325, 10.1113/jphysiol.1902.sp000920 Beglinger, 2008, Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects, Clin Pharmacol Ther, 84, 468, 10.1038/clpt.2008.35 Bell, 1983, Hamster preproglucagon contains the sequence of glucagon and two related peptides, Nature, 302, 716, 10.1038/302716a0 Bergenstal, 2009, Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea, Curr Med Res Opin, 25, 65, 10.1185/03007990802597951 Blase, 2005, Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects, J Clin Pharmacol, 45, 570, 10.1177/0091270004274432 Bor, 2007, Association of heartburn during pregnancy with the risk of gastroesophageal reflux disease, Clin Gastroenterol Hepatol, 5, 1035, 10.1016/j.cgh.2007.05.003 Bozkurt, 2002, GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat, Regul Pept, 107, 129, 10.1016/S0167-0115(02)00095-2 Brener, 1983, Regulation of the gastric emptying of glucose, Gastroenterology, 85, 76, 10.1016/S0016-5085(83)80232-7 Brown, 1970, Further purification of a polypeptide demonstrating enterogastrone activity, J Physiol, 209, 57, 10.1113/jphysiol.1970.sp009155 Brubaker, 2004, Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system, Endocrinology, 145, 2653, 10.1210/en.2004-0015 Brubaker, 2002, Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor, J Clin Endocrinol Metab, 87, 3078, 10.1210/jcem.87.7.8584 Buchman, 2010, Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease, Inflamm Bowel Dis, 16, 962, 10.1002/ibd.21117 Bunck, 2011, Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes, Diabetes Care, 34, 2041, 10.2337/dc11-0291 Bunck, 2009, One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial, Diabetes Care, 32, 762, 10.2337/dc08-1797 Buse, 2011, Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial, Ann Intern Med, 154, 103, 10.7326/0003-4819-154-2-201101180-00300 Buse, 2010, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks, Diabetes Care, 33, 1255, 10.2337/dc09-1914 Buse, 2009, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 374, 39, 10.1016/S0140-6736(09)60659-0 Collins, 1983, Gastric emptying in normal subjects – a reproducible technique using a single scintillation camera and computer system, Gut, 24, 1117, 10.1136/gut.24.12.1117 Creutzfeldt, 1979, The incretin concept today, Diabetologia, 16, 75, 10.1007/BF01225454 Creutzfeldt, 2005, The [pre-] history of the incretin concept, Regul Pept, 128, 87, 10.1016/j.regpep.2004.08.004 Davidson, 2011, Cardiovascular effects of glucagonlike peptide-1 agonists, Am J Cardiol, 108, 33B, 10.1016/j.amjcard.2011.03.046 Deacon, 2011, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review, Diabetes Obes Metab, 13, 7, 10.1111/j.1463-1326.2010.01306.x Deacon, 1996, Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig, Am J Physiol, 271, E458 Deane, 2010, Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia, J Clin Endocrinol Metab, 95, 215, 10.1210/jc.2009-1503 Donnelly, 2012, The structure and function of the glucagon-like peptide-1 receptor and its ligands, Br J Pharmacol, 166, 27, 10.1111/j.1476-5381.2011.01687.x Drucker, 1988, Glucagon gene expression in vertebrate brain, J Biol Chem, 263, 13475, 10.1016/S0021-9258(18)68261-4 Drucker, 1989, Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine, Proc Natl Acad Sci USA, 86, 3953, 10.1073/pnas.86.11.3953 Drucker, 2008, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, Lancet, 372, 1240, 10.1016/S0140-6736(08)61206-4 Drucker, 1996, Induction of intestinal epithelial proliferation by glucagon-like peptide 2, Proc Natl Acad Sci USA, 93, 7911, 10.1073/pnas.93.15.7911 Drucker, 2011, The safety of incretin-based therapies – review of the scientific evidence, J Clin Endocrinol Metab, 96, 2027, 10.1210/jc.2011-0599 Dupre, 1973, Stimulation of insulin secretion by gastric inhibitory polypeptide in man, J Clin Endocrinol Metab, 37, 826, 10.1210/jcem-37-5-826 Ebert, 1983, Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption, Diabetologia, 24, 449, 10.1007/BF00257346 Moore, 1906, On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane, Biochem J, 1, 28, 10.1042/bj0010028 Edwards, 1999, Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39, Diabetes, 48, 86, 10.2337/diabetes.48.1.86 Efrat, 1988, Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells, Neuron, 1, 605, 10.1016/0896-6273(88)90110-9 Elrick, 1964, Plasma insulin response to oral and intravenous glucose administration, J Clin Endocrinol Metab, 24, 1076, 10.1210/jcem-24-10-1076 Flint, 1998, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans, J Clin Invest, 101, 515, 10.1172/JCI990 Giralt, 1999, Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat, Dig Dis Sci, 44, 322, 10.1023/A:1026654417697 Gulpinar, 2000, Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats, Am J Physiol Gastrointest Liver Physiol, 278, G924, 10.1152/ajpgi.2000.278.6.G924 Gutniak, 1994, Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM, Diabetes Care, 17, 1039, 10.2337/diacare.17.9.1039 Hansen, 1999, Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine, Endocrinology, 140, 5356, 10.1210/endo.140.11.7143 Hare, 2009, Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus, J Clin Endocrinol Metab, 94, 4679, 10.1210/jc.2009-0921 Hartmann, 2000, In vivo and in vitro degradation of glucagon-like peptide-2 in humans, J Clin Endocrinol Metab, 85, 2884 Hellstrom, 2009, Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study, Aliment Pharmacol Ther, 29, 198, 10.1111/j.1365-2036.2008.03870.x Hellstrom, 2008, GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome, Neurogastroenterol Motil, 20, 649, 10.1111/j.1365-2982.2007.01079.x Holst, 2007, The physiology of glucagon-like peptide 1, Physiol Rev, 87, 1409, 10.1152/physrev.00034.2006 Holst, 2010, Glucagon and glucagon-like peptides 1 and 2, Results Probl Cell Differ, 50, 121 Holst, 2011, Neuroprotective properties of GLP-1: theoretical and practical applications, Curr Med Res Opin, 27, 547, 10.1185/03007995.2010.549466 Holst, 2011, Regulation of glucagon secretion by incretins, Diabetes Obes Metab, 13, 89, 10.1111/j.1463-1326.2011.01452.x Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37), Nature, 361, 362, 10.1038/361362a0 Hornby, 2011, The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease, Expert Opin Ther Targets, 15, 637, 10.1517/14728222.2011.556620 Horowitz, 1991, Disordered gastric emptying: mechanical basis, assessment and treatment, Baillieres Clin Gastroenterol, 5, 371, 10.1016/0950-3528(91)90034-X Hoyt, 1996, Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum, Diabetes, 45, 434, 10.2337/diab.45.4.434 Hupe-Sodmann, 1995, Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides, Regul Pept, 58, 149, 10.1016/0167-0115(95)00063-H Hvidberg, 1994, Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man, Metabolism, 43, 104, 10.1016/0026-0495(94)90164-3 Irwin, 1999, Lamprey proglucagon and the origin of glucagon-like peptides, Mol Biol Evol, 16, 1548, 10.1093/oxfordjournals.molbev.a026067 Jelsing, 2012, Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight, Diabetes Obes Metab, 14, 531, 10.1111/j.1463-1326.2012.01557.x Jones, 1989, The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia, 32, 668, 10.1007/BF00274255 Jones, 2002, A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus, Am J Med, 113, 449, 10.1016/S0002-9343(02)01228-7 Kielgast, 2010, Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients, J Clin Endocrinol Metab, 95, 2492, 10.1210/jc.2009-2440 Knop, 2011, Prohormone convertase 2 positive enteroendocrine cells are more abundant in patients with type 2 diabetes: a potential source of gut-derived glucagon?, Diabetologia, 54, S1 Koska, 2010, Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes, Diabetes Care, 33, 1028, 10.2337/dc09-1961 Kreymann, 1987, Glucagon-like peptide-1 7-36: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 La Barre, 1932, Sur les possibilités d‘un traitement du diabète par l‘incrétine, Bull Acad R Med Belg, 12, 620 Lee, 1992, Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice, J Biol Chem, 267, 10705, 10.1016/S0021-9258(19)50075-8 Lefebvre, 1995, Glucagon and its family revisited, Diabetes Care, 18, 715, 10.2337/diacare.18.5.715 Li, 2003, Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis, J Biol Chem, 278, 471, 10.1074/jbc.M209423200 Linnebjerg, 2008, Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes, Regul Pept, 151, 123, 10.1016/j.regpep.2008.07.003 Little, 2006, The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed, Am J Physiol Endocrinol Metab, 291, E647, 10.1152/ajpendo.00099.2006 Loew, 1939, The effect of duodenal instillation of hydrochloric acid upon the fasting blood sugar of dogs, Am J Physiol, 126, 270, 10.1152/ajplegacy.1939.126.2.270 Loew, 1940, The effect of acid stimulation of the duodenum upon experimental hyperglycemia and utilization of glucose, Am J Physiol, 128, 298, 10.1152/ajplegacy.1939.128.2.298 Loew, 1940, Is a duodenal hormone involved in carbohydrate metabolism, Am J Physiol, 129, 659, 10.1152/ajplegacy.1940.129.3.659 Lojda, 1979, Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase). II. Blood vessels, Histochemistry, 59, 153, 10.1007/BF00495663 Lorenz, 2012, Effects of lixisenatide once daily on gastric emptying and relationships to postprandial glycemia in type 2 diabetes mellitus, Diabetes, June Lund, 2011, The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes, Am J Physiol Endocrinol Metab, 300, E1038, 10.1152/ajpendo.00665.2010 Lund, 1982, Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem, Proc Natl Acad Sci USA, 79, 345, 10.1073/pnas.79.2.345 Ma, 2012, Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes, Diabet Med, 29, 604, 10.1111/j.1464-5491.2011.03496.x Ma, 2009, Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes, Diabetes Care, 32, 1600, 10.2337/dc09-0723 Marathe, 2011, Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function, Exp Diabetes Res, 2011, 279530, 10.1155/2011/279530 Mardini, 2008, Teduglutide in intestinal adaptation and repair: light at the end of the tunnel, Expert Opin Investig Drugs, 17, 945, 10.1517/13543784.17.6.945 McIntyre, 1964, New interpretation of oral glucose tolerance, Lancet, 41, 20, 10.1016/S0140-6736(64)90011-X Meier, 2003, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes, J Clin Endocrinol Metab, 88, 2719, 10.1210/jc.2003-030049 Meier, 2003, Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia, Diabetologia, 46, 798, 10.1007/s00125-003-1103-y Meier, 2005, Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects, Diabetes, 54, 2212, 10.2337/diabetes.54.7.2212 Meier, 2006, Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis, Diabetes, 55, 1051, 10.2337/diabetes.55.04.06.db05-1449 Meier, 2005, Glucagon-like peptide 1(GLP-1) in biology and pathology, Diabetes Metab Res Rev, 21, 91, 10.1002/dmrr.538 Meier, 2006, Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans, Gastroenterology, 130, 44, 10.1053/j.gastro.2005.10.004 Meneilly, 2003, Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes, Diabetes Care, 26, 2835, 10.2337/diacare.26.10.2835 Mentlein, 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur J Biochem, 214, 829, 10.1111/j.1432-1033.1993.tb17986.x Mojsov, 1986, Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing, J Biol Chem, 261, 11880, 10.1016/S0021-9258(18)67324-7 Monnier, 2003, Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c), Diabetes Care, 26, 881, 10.2337/diacare.26.3.881 Munroe, 1999, Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2, Proc Natl Acad Sci USA, 96, 1569, 10.1073/pnas.96.4.1569 Myojo, 1997, Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro, J Gastroenterol, 32, 300, 10.1007/BF02934484 Naslund, 1999, Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men, Int J Obes Relat Metab Disord, 23, 304, 10.1038/sj.ijo.0800818 Nauck, 1986, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes, Diabetologia, 29, 46, 10.1007/BF02427280 Nauck, 2011, Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications, Am J Med, 124, S3, 10.1016/j.amjmed.2010.11.002 Nauck, 2007, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study, Diabetologia, 50, 259, 10.1007/s00125-006-0510-2 Nauck, 1993, Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, J Clin Invest, 91, 301, 10.1172/JCI116186 Nauck, 1986, Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses, J Clin Endocrinol Metab, 63, 492, 10.1210/jcem-63-2-492 Nauck, 2011, Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans, Diabetes, 60, 1561, 10.2337/db10-0474 Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981 Nauck, 2011, Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down, Diabetologia, 54, 10, 10.1007/s00125-010-1896-4 Nauck, 1996, Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM, Diabetologia, 39, 1546, 10.1007/s001250050613 Nian, 1999, Divergent regulation of human and rat proglucagon gene promoters in vivo, Am J Physiol, 277, G829 Nicolaus, 2011, Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying, J Clin Endocrinol Metab, 96, 229, 10.1210/jc.2010-0841 Nuche-Berenguer, 2009, Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states, Calcif Tissue Int, 84, 453, 10.1007/s00223-009-9220-3 Nuche-Berenguer, 2010, Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states, Regul Pept, 159, 61, 10.1016/j.regpep.2009.06.010 Orskov, 1993, Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable, Diabetes, 42, 658, 10.2337/diab.42.5.658 Pedersen, 2008, Porcine glucagon-like peptide-2: structure, signaling, metabolism and effects, Regul Pept, 146, 310, 10.1016/j.regpep.2007.11.003 Perry, 2003, Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron, J Neurosci Res, 72, 603, 10.1002/jnr.10611 Pilichiewicz, 2007, Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men, Am J Physiol Endocrinol Metab, 293, E743, 10.1152/ajpendo.00159.2007 Plamboeck, 2005, Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig, Diabetologia, 48, 1882, 10.1007/s00125-005-1847-7 Roberge, 1991, Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients, Endocrinology, 128, 3169, 10.1210/endo-128-6-3169 Roberge, 1993, Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop, Endocrinology, 133, 233, 10.1210/endo.133.1.8319572 Rocca, 1999, Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion, Endocrinology, 140, 1687, 10.1210/endo.140.4.6643 Ross, 1977, Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus, Diabetes, 26, 525, 10.2337/diab.26.6.525 Rouille, 1995, Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide, J Biol Chem, 270, 26488, 10.1074/jbc.270.44.26488 Rouille, 1994, Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells, Proc Natl Acad Sci USA, 91, 3242, 10.1073/pnas.91.8.3242 Rowland, 2008, Life in the crypt: a role for glucagon-like peptide-2, Mol Cell Endocrinol, 288, 63, 10.1016/j.mce.2008.02.014 Rowland, 2011, The “cryptic” mechanism of action of glucagon-like peptide-2, Am J Physiol Gastrointest Liver Physiol, 301, G1, 10.1152/ajpgi.00039.2011 Salehi, 2008, Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion, J Clin Endocrinol Metab, 93, 4909, 10.1210/jc.2008-0605 Sander, 1997, Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development, Genes Dev, 11, 1662, 10.1101/gad.11.13.1662 Schick, 2003, Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats, Am J Physiol Regul Integr Comp Physiol, 284, R1427, 10.1152/ajpregu.00479.2002 Schmidt, 2003, Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety, Regul Pept, 116, 21, 10.1016/S0167-0115(03)00175-7 Schmidt, 1985, Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets, Diabetologia, 28, 704, 10.1007/BF00291980 Schroeder, 1984, Localization of the human glucagon gene (GCG) to chromosome segment 2q36-37, Cytogenet Cell Genet, 38, 76, 10.1159/000132034 Schwartz, 2000, Central nervous system control of food intake, Nature, 404, 661, 10.1038/35007534 Shyangdan, 2010, Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis, BMC Endocr Disord, 10, 20, 10.1186/1472-6823-10-20 Sigalet, 2012, Nonruminant nutrition symposium: the role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander, J Anim Sci, 90, 1224, 10.2527/jas.2011-4704 Sowden, 2007, Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor, Am J Physiol Regul Integr Comp Physiol, 292, R962, 10.1152/ajpregu.00405.2006 Steinert, 2010, Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects, Am J Clin Nutr, 92, 810, 10.3945/ajcn.2010.29663 Stevens, 2012, The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study, Aliment Pharmacol Ther, 36, 379, 10.1111/j.1365-2036.2012.05198.x Teramoto, 2011, Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia, J Cereb Blood Flow Metab, 31, 1696, 10.1038/jcbfm.2011.51 Theodorakis, 2006, Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP, Am J Physiol Endocrinol Metab., 290, E550, 10.1152/ajpendo.00326.2004 Thorens, 1992, Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1, Proc Natl Acad Sci USA, 89, 8641, 10.1073/pnas.89.18.8641 Todd, 1998, Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes, Clin Sci (Lond), 95, 325, 10.1042/CS19980051 Toft-Nielsen, 1999, Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients, Diabetes Care, 22, 1137, 10.2337/diacare.22.7.1137 Toft-Nielsen, 2001, Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes, J Clin Endocrinol Metab, 86, 3853, 10.1210/jcem.86.8.7743 Torekov, 2011, Obesity – an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential, Obes Rev, 12, 593, 10.1111/j.1467-789X.2011.00860.x Trinh, 2003, Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium, Diabetes, 52, 425, 10.2337/diabetes.52.2.425 Tsai, 1997, Intestinal growth-promoting properties of glucagon-like peptide-2 in mice, Am J Physiol, 273, E77 Turner, 1999, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group, JAMA, 281, 2005, 10.1001/jama.281.21.2005 Turton, 1996, A role for glucagon-like peptide-1 in the central regulation of feeding, Nature, 379, 69, 10.1038/379069a0 Vollmer, 2008, Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance, Diabetes, 57, 678, 10.2337/db07-1124 Wang, 1999, Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells, Endocrinology, 140, 4904, 10.1210/endo.140.10.7158 White, 1986, Structure of the human glucagon gene, Nucleic Acids Res, 14, 4719, 10.1093/nar/14.12.4719 Williams, 2009, Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety, Endocrinology, 150, 1680, 10.1210/en.2008-1045 Wishart, 1998, Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1, Peptides, 19, 1049, 10.1016/S0196-9781(98)00052-7 Witte, 2011, Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion, Scand J Gastroenterol, 46, 428, 10.3109/00365521.2010.537680 Wu, 2010, Dietary effects on incretin hormone secretion, Vitam Horm, 84, 81, 10.1016/B978-0-12-381517-0.00003-5 Wu, 2012, Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans, Am J Clin Nutr, 95, 78, 10.3945/ajcn.111.021543 Xiao, 1999, Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans, Gastroenterology, 117, 99, 10.1016/S0016-5085(99)70555-X Yusta, 2000, Enteroendocrine localization of GLP-2 receptor expression in humans and rodents, Gastroenterology, 119, 744, 10.1053/gast.2000.16489 Zander, 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study, Lancet, 359, 824, 10.1016/S0140-6736(02)07952-7 Zhou, 2006, Irwin DM. Intron 1 sequences are required for pancreatic expression of the human proglucagon gene, Am J Physiol Regul Integr Comp Physiol, 290, R634, 10.1152/ajpregu.00596.2005